Correlation Between Aerovate Therapeutics and Scopus Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aerovate Therapeutics and Scopus Biopharma, you can compare the effects of market volatilities on Aerovate Therapeutics and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Scopus Biopharma.

Diversification Opportunities for Aerovate Therapeutics and Scopus Biopharma

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Aerovate and Scopus is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and Scopus Biopharma

If you would invest (100.00) in Scopus Biopharma on December 1, 2024 and sell it today you would earn a total of  100.00  from holding Scopus Biopharma or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Aerovate Therapeutics  vs.  Scopus Biopharma

 Performance 
       Timeline  
Aerovate Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Aerovate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.
Scopus Biopharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Aerovate Therapeutics and Scopus Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aerovate Therapeutics and Scopus Biopharma

The main advantage of trading using opposite Aerovate Therapeutics and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.
The idea behind Aerovate Therapeutics and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas